Last Updated: June 12, 2026

OLMESARTAN Drug Patent Profile

Name: OLMESARTAN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Olmesartan patents expire, and when can generic versions of Olmesartan launch?

Olmesartan is a drug marketed by Accord Hlthcare, Alembic, Alkem Labs Ltd, Amneal, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd V, Inventia, Jubilant Generics, Lupin, Macleods Pharms Ltd, Micro Labs, MSN, Prinston Inc, Qilu, Rising, Sandoz, Sciegen Pharms, Sunshine, Teva Pharms Usa, Torrent, Umedica, Zydus Pharms, Hangzhou Binjiang, Natco Pharma Usa, Ph Health, and Piramal. and is included in forty-eight NDAs.

The generic ingredient in OLMESARTAN is amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. There are fifty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for OLMESARTAN?
What are the global sales for OLMESARTAN?
What is Average Wholesale Price for OLMESARTAN?

Summary for OLMESARTAN

US Patents:	0
Applicants:	29
NDAs:	48
Drug Prices:	Drug price information for OLMESARTAN
DailyMed Link:	OLMESARTAN at DailyMed

Drug patent expirations by year for OLMESARTAN

US Patents and Regulatory Information for OLMESARTAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Umedica	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207135-003	Jul 18, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	217398-002	Sep 26, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Micro Labs	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	206372-002	Sep 17, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Jubilant Generics	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	205482-002	Apr 24, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for OLMESARTAN

Is Olmesartan an angiotensin receptor blocker?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.